You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 4, 2025

Details for Patent: 7,560,429


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,560,429
Title:Orodispersible dosage forms of desmopressin acetate
Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
Inventor(s): Nilsson; Anders (Lund, SE), Lindner; Hans (Leichlingen, DE), Wittendorff; Jorgen (Hvidovre, DK)
Assignee: Ferring B.V. (Hoofddorp, NL)
Application Number:10/513,437
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,560,429
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Process; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 7,560,429

To delve into the details of the scope and claims of United States Patent 7,560,429, it is essential to break down the key components and context surrounding this patent.

Patent Overview

United States Patent 7,560,429, like any other patent, is a grant of rights for an invention, issued by the U.S. Patent and Trademark Office (USPTO)[4].

Patent Type

The patent in question is likely a utility patent, given that it is the most common type of patent and covers functional inventions. Utility patents have a duration of twenty years from the date of filing but are not enforceable until the day of issuance[4].

Claims Analysis

Independent and Dependent Claims

Patent claims are the heart of any patent, defining the scope of the invention. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims. The number and length of independent claims can be metrics for measuring patent scope, with narrower claims often associated with a higher probability of grant and a shorter examination process[3].

Claim Language and Scope

The language used in the claims is crucial. It must be clear and specific enough to define the invention but broad enough to cover the inventor's contribution. The scope of the patent is directly tied to the claim language, and overly broad claims can lead to issues of clarity and validity[3].

Patent Scope and Quality

The debate over patent quality often revolves around the breadth and clarity of patent claims. Narrower claims at publication are generally associated with a higher probability of grant and shorter examination processes. This suggests that the scope of the patent, as defined by its claims, plays a significant role in its overall quality and enforceability[3].

Inventorship and Conception

For a patent to be valid, it must list the "true and only" inventors. The conception of the idea is a critical step in determining inventorship, requiring the identification of each person who conceived the idea or ideas of the patent claims. Conception is complete when an idea is sufficiently definite and permanent to permit one with ordinary skill in the field to reduce it to practice without undue experimentation[5].

Patent Term and Adjustments

The patent term for utility patents is twenty years from the date of filing. However, Patent Term Adjustments (PTA) can extend this term due to delays during the prosecution process. This is relevant when considering the overall lifespan and enforceability of the patent, especially in cases where multiple related patents are involved[1].

Obviousness-Type Double Patenting (ODP)

ODP is a doctrine that prevents the issuance of multiple patents for the same invention or for inventions that are not patentably distinct from each other. This is particularly relevant when dealing with continuation-in-part patents or patents that claim priority from the same application. The USPTO and courts carefully analyze these situations to ensure that no patent extends beyond its rightful term[1].

Examination and Reexamination

The USPTO examines patent applications to determine if the invention is patentable. During this process, the examiner may reject claims based on various grounds, including obviousness-type double patenting. Reexamination proceedings can also be initiated to re-evaluate the patentability of issued patents, which can impact the validity and scope of the patent claims[4].

Litigation and Enforcement

Patent enforcement involves excluding others from making, using, or selling the invention. However, errors in inventorship, claim language, or other aspects can render a patent unenforceable. Litigation often revolves around these issues, and courts must determine the validity and scope of the patent based on the evidence presented[5].

Industry Impact

The scope and claims of a patent like 7,560,429 can significantly impact the industry in which it operates. Broad or overly broad claims can lead to increased licensing and litigation costs, potentially stifling innovation. Conversely, well-defined and narrow claims can provide clear boundaries, encouraging further innovation and competition[3].

Statistical Insights

Studies have shown that narrower claims are associated with a higher probability of grant and shorter examination processes. For example, a large-scale analysis found that patents with narrower claims at publication had a higher grant rate and faster examination times compared to those with broader claims[3].

Expert Opinions

Industry experts often emphasize the importance of clear and specific claim language. As noted by legal experts, "conception is complete when an idea is sufficiently definite and permanent to permit one with ordinary skill in the field to reduce it to practice without undue experimentation"[5].

Example from Case Law

In the case of In re Cellect, the Federal Circuit Court of Appeals affirmed the rejection of claims due to obviousness-type double patenting. This case highlights the importance of analyzing the interrelated nature of patents and their claims to ensure that no patent extends beyond its rightful term[1].

Key Takeaways

  • Clear Claim Language: The scope of a patent is directly tied to the clarity and specificity of its claims.
  • Inventorship: Correctly identifying the true and only inventors is crucial for the validity of the patent.
  • Patent Term Adjustments: Delays during prosecution can extend the patent term, but must be carefully analyzed to avoid ODP issues.
  • Industry Impact: The breadth and clarity of patent claims can significantly affect innovation and competition within an industry.
  • Litigation: Errors in claim language or inventorship can render a patent unenforceable, emphasizing the need for thorough examination and reexamination processes.

Frequently Asked Questions

What is the significance of independent claims in a patent?

Independent claims define the invention and stand alone, while dependent claims further limit these independent claims. The number and length of independent claims can be metrics for measuring patent scope[3].

How does obviousness-type double patenting affect patent validity?

ODP prevents the issuance of multiple patents for the same invention or for inventions that are not patentably distinct from each other, ensuring that no patent extends beyond its rightful term[1].

What role does inventorship play in patent validity?

Correctly identifying the true and only inventors is crucial for the validity of the patent. Errors in inventorship, especially those involving deceptive intent, can render a patent unenforceable[5].

How do Patent Term Adjustments impact the lifespan of a patent?

PTA can extend the patent term due to delays during the prosecution process, but these adjustments must be carefully analyzed to avoid ODP issues[1].

What are the implications of broad or overly broad patent claims?

Broad or overly broad claims can lead to increased licensing and litigation costs, potentially stifling innovation. Well-defined and narrow claims, on the other hand, provide clear boundaries and encourage further innovation and competition[3].

Cited Sources:

  1. In re Cellect - United States Court of Appeals for the Federal Circuit[1]
  2. U.S. Patent and Trademark Office (USPTO) - USAGov[2]
  3. Patent Claims and Patent Scope - SSRN[3]
  4. Patent Law in the United States - BitLaw[4]
  5. Determining Inventorship for US Patent Applications - Oregon State University[5]

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 7,560,429

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

Foreign Priority and PCT Information for Patent: 7,560,429

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0210397.6May 7, 2002
PCT/IB02/04036Sep 20, 2002
PCT Information
PCT FiledMay 07, 2003PCT Application Number:PCT/IB03/02368
PCT Publication Date:November 20, 2003PCT Publication Number: WO03/094886

International Family Members for US Patent 7,560,429

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Argentina 039092 ⤷  Try for Free
Argentina 039794 ⤷  Try for Free
Argentina 107948 ⤷  Try for Free
Australia 2002337419 ⤷  Try for Free
Australia 2003233118 ⤷  Try for Free
Australia 2003299480 ⤷  Try for Free
Austria 333886 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 7 of 7 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.